Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.34 |
| ▸ | ACE | P12821 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13232167 | 0.95 | EPHX1 (0.38) | CYP2D6CYP2C9HIF1ANPC1HPGD | |
| SCHEMBL10021100 | 0.83 | TSHR (0.39) | NPC1RAB9AL3MBTL1ESR1ESR2 | |
| SCHEMBL18660420 | 0.81 | ALDH1A1 (0.40) | HIF1ASMN1; SMN2MEN1KMT2AESR2 | |
| SCHEMBL317837 | 0.79 | ESR1 (0.31) | ESR1ESR2 | |
| SCHEMBL10021105 | 0.78 | L3MBTL1 (0.38) | NPC1RAB9AL3MBTL1ESR1ESR2 | |
| SCHEMBL6055426 | 0.76 | KDM4E (0.44) | NPC1HPGDRAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL18660141 | 0.76 | CSNK1E (0.44) | CNR2ALDH1A1 | |
| SCHEMBL317660 | 0.75 | GPR84 (0.35) | CYP2D6POLBKDM4EALDH1A1 | |
| SCHEMBL13693153 | 0.74 | KIF11 (0.35) | SMN1; SMN2MEN1KMT2AKIF11 | |
| SCHEMBL6055419 | 0.72 | LMNA (0.46) | CYP2D6HIF1ANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796696-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. | 2017-03-02 | — | — | US | disclosed |
| US-9365485-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2014-10-30 | — | — | US | disclosed |
| US-8722726-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-8362054-B2 | Therapeutic substituted lactams | ALLERGAN, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20100168189-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7713968-B2 | Substituted arylcyclopentenes as therapeutic agents | ALLERGAN, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20090270387-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ALLERGAN, INC. (US) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323510-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | CYP2D6 18/4885CYP2C9 260/4885HIF1A 1883/4885 |
| US-20170057941-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | CYP2D6 18/4885CYP2C9 260/4885HIF1A 1883/4885 |
| US-20090270387-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, UGT2B7, GBA1 | CYP2D6 15/4885CYP2C9 139/4885HIF1A 2335/4885 |
| US-20100168189-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | PIGO, GARS1, CLPP | CYP2D6 632/4885CYP2C9 696/4885HIF1A 3185/4885 |
| US-20100137347-A1 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS | ABCB1, THPO, UGT2B7 | CYP2D6 12/4885CYP2C9 233/4885HIF1A 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.